Hydroxyurea-induced denaturation of normal and sickle cell hemoglobins in vitro

Journal of Clinical Laboratory Analysis

Volumn 11, Issue 4, 1997, Pages 208-213

  Roa, D ^a   Kopsombut, P ^a   Aguinaga, M D P ^a   Turner, E A ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Hemoglobin variants; High performance liquid chromatography; Hydroxyurea

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN VARIANT; HYDROXYUREA;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; ERYTHROCYTE DEFORMABILITY; HEMOGLOBINOPATHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOELECTRIC FOCUSING; POLYMERIZATION; PROTEIN DENATURATION; RECEPTOR SOLUBILIZATION; SCREENING; SICKLE CELL ANEMIA;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; HEMOGLOBIN A; HEMOGLOBIN, SICKLE; HEMOGLOBINS; HUMANS; HYDROXYUREA; MALE; PROTEIN DENATURATION;

EID: 0030952523     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(1997)11:4<208::AID-JCLA6>3.0.CO;2-4     Document Type: Article

References (30)

1. Herman EC, Conley CL: Hereditary resistance of fetal hemoglobin: A family study. Am J Med Sci 29:9-17, 1960.
2. Watson J: The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci 215:419, 1948.
3. DeSimone J, Heller P, Hall L, Zweiss D: 5-Azacytidine stimulates fetal hemoglobin (Hb F) synthesis in anemic baboons. Proc Natl Acad Sci USA 79:4428-4431, 1982.
4. Carr BI, Reilly JG, Smith SS, Winberg C, Riggs A: The tumorigenicity of 5-azacytidine in the male Fischer rat. Carcinogenesis 5:1583, 1984.
5. International Agency for Research on Cancer. Some antineoplastic and immunosuppressive agents. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Lyon IARC 6:37-44, 267-284, 1981.
6. National Cancer Institute: Bioassay of 5-azacytidine for possible carcinogenicity CAS No 320-67-21. Carcinogenesis technical report series no. 42 U.S. Department of Commerce Technical Information Service Publication no. PB 279-526, 1978.
7. Asakura T, Ohnishi ST, Adachi K, Ozguc M, Hashimoto K, Devlin MT, Schwartz E: Effect of piracetam on sickle cell erythrocytes and sickle hemoglobin. Biochim Biophys Acta 664:397-405, 1981.
8. Cerami A: Review of the development of cyanate as a drug in the treatment of sickle cell anemia. Ann N Y Acad Sci 538-544, 1974.
9. Freedman ML: New drugs in the treatment of sickle cell anemia. Am J Med Sci 265:371-373, 1973.
10. Gini EK, Sonnet J: Use of piracetam improves sickle cell deformability in vitro and in vivo. J Clin Pathol 40:99-102, 1987.
11. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Lacroix L, Bunn HF: Hydroxyurea and erythropoietin therapy in sickle cell anemia. Semin Oncol 19:74-81, 1992.
12. Lee MY, Uvelli DA, Agodoa LCY, Scribner BH, Finch CA, Babb AL: Clinical studies of a continuous extracorporeal cyanate treatment system for patients with sickle cell disease J Lab Clin Med 100:334-344, 1982.
13. Levine SN, Berkowitz LR, Orringer EP: Inhibition of erythrocyte calcium transport by cetiedil. Pharmacology 36:44-51, 1988.
14. Nalbandian RM, Henry RL, Bamhart MI, Camp FR, Jr: Sickle cell disease clinical advances by the Murayama molecular hypothesis. Milt Med 137:215-220, 1972.
15. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW: Augmentation by erythropoietin of the fetal hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 328:73-80, 1993
16. Platt OS, Orkin SH, Dover G, Beardsly GP, Miller B, Nathan DG: Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 74:652-656, 1984.
17. Rose C: Hydroxyurea therapy in highly unstable hemoglobin carriers. Blood 88:2807-2808, 1996.
18. Charache S: Pharmacological modification of hemoglobin F expression in sickle cell anemia: An update on hydroxyurea studies. Experientia 49:126-132, 1993.
19. Ballas SK, Dover GJ, Charache S: Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 32:104-111, 1989.
20. Orringer EP, Blythe DSB, Johnson EE, Phillips G Jr, Dover J, Parker JC: Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood 78:212-216, 1991.
21. Dover GJ, Charache S: Hydroxyurea induction of fetal hemoglobin synthesis in sickle cell disease. Semin Oncol 19:61-66, 1992.
22. Merz B: Promising drug combination for sickle cell anemia. JAMA 261:3069, 1989.
23. Rodgers GP: Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: The National Institutes of Health experience. Semin Oncol 19:67-73, 1992.
24. Charache S, Dover GJ, Moore RD, Eckert S, Ballard SK: Hydroxyurea effects on hemoglobin F production in patients with sickle cell anemia. Blood 79:2555-2565, 1992.
25. Dover GJ, Charache S: Increasing fetal hemoglobin production in sickle cell disease: Results of clinical trials. Prog Clin Biol Res 251:455-466, 1987.
26. El-Hazmi MA, Warsy AS, al-Momen A, Harakati M: Hydroxyurea for the treatment of sickle cell disease. Acta Haematol 88:170-174, 1992.
27. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN: Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 318:96-99, 1988.
28. Charache S: Hydroxyurea as treatment for sickle cell anemia. Hematol Oncol Clin North Am 5:571-583, 1991.
29. Roa D, Turner EA, Aguinaga MdP: Reference ranges for Hb variants by HPLC in African Americans. J Ann Clin Lab Sci 25:228-235, 1995.
30. Roa D, Turner EA, Aguinaga MdP: Hemoglobin variant detection from dried blood specimens by high performance liquid chromatography J Ann Clin Lab Sci 23:433-438, 1993.